EOLS HealthcareBeta data

Evolus, Inc.

$7.37+2.93%

Price as of close on Nov 3, 2026 · Financials updated Nov 4, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 486.8M USD
Enterprise value: 606.4M USD
Full-time employees: 353

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.34 vs a peer median of 0.63) and less short-term liquidity (current ratio 1.70 vs a peer median of 2.59)higher risk: bigger price swings (beta 1.34 vs peers 0.63) and less liquidity (current ratio 1.70 vs peers 2.59)

Ranks #995 of 1,157 healthcare companies (bottom 15%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
Evolus's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Evolus looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
Evolus reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

29/ 100

Oct 5 29 → Nov 4 29

Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-7.2%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-2.1%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-4.5%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-6.4%

Yahoo FinanceOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

77/100

Moderate

2/3 inputs reported · Partial data

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0976 · MAD: 0.2991

3-year revenue growth26.0%

Yahoo Finance · 3 fiscal years to Dec 2025Reported value33% base weight · Z-score 2.40Sector median: 0.0584 · MAD: 0.0840

Revenue growth11.6%

Yahoo Finance · fiscal year to Dec 2025Reported value33% base weight · Z-score 0.57Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

29/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Operating margin
▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-12.7%

Yahoo Finance · fiscal year to Dec 2025Reported value33% base weight · Z-score -1.62Sector median: 0.0706 · MAD: 0.1217

Return on assets-5.7%

Yahoo Finance · trailing 12 monthsReported value33% base weight · Z-score -1.37Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-14.6%

Yahoo Finance · trailing 12 monthsReported value33% base weight · Z-score -1.92Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin66.4%

Yahoo Finance · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equityUnavailable

Missing · left out of the scoreInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Debt / equity
▼ Beta
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.34

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -2.12Sector median: 0.6250 · MAD: 0.3380

Current ratio1.70×

Yahoo FinanceReported value33% base weight · Z-score -0.64Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Evolus

Is Evolus getting weaker?: Filing-by-filing changes are tracked only for companies that file with the US SEC. Its overall score is unchanged at 29/100 since Oct 28, 2026.
How is Evolus valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -7.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.2% vs peers 1.5% (weaker than 100% of peers).
Is Evolus growing?: Yes, faster than most of its peers. Growth scores 77/100 against 1,393 healthcare peers. 3-year revenue growth 26.0% vs a peer median of 5.8% (stronger than 85% of peers).3-year revenue growth 26.0% vs peers 5.8% (stronger than 85% of peers).
How profitable is Evolus?: Less profitable than most of its peers. Profitability scores 29/100 against 1,393 healthcare peers. Operating margin -12.7% vs a peer median of 7.1% (weaker than 76% of peers).Operating margin -12.7% vs peers 7.1% (weaker than 76% of peers).
How risky is Evolus?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.34 vs a peer median of 0.63 (weaker than 84% of peers).Beta 1.34 vs peers 0.63 (weaker than 84% of peers). A relative measure, not a bankruptcy probability.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Detailed annual statements come from structured SEC filing data, which most US companies and some foreign filers provide. They aren’t available for this company yet.

EOLS price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.34 vs a peer median of 0.63) and less short-term liquidity (current ratio 1.70 vs a peer median of 2.59)higher risk: bigger price swings (beta 1.34 vs peers 0.63) and less liquidity (current ratio 1.70 vs peers 2.59)

Ranks #995 of 1,157 healthcare companies (bottom 15%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

Evolus's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Evolus looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss over the last 12 months.

Evolus reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Evolus

Is Evolus getting weaker?

Filing-by-filing changes are tracked only for companies that file with the US SEC. Its overall score is unchanged at 29/100 since Oct 28, 2026.

How is Evolus valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -7.2% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -7.2% vs peers 1.5% (weaker than 100% of peers).

Is Evolus growing?

Yes, faster than most of its peers. Growth scores 77/100 against 1,393 healthcare peers. 3-year revenue growth 26.0% vs a peer median of 5.8% (stronger than 85% of peers).3-year revenue growth 26.0% vs peers 5.8% (stronger than 85% of peers).

How profitable is Evolus?

Less profitable than most of its peers. Profitability scores 29/100 against 1,393 healthcare peers. Operating margin -12.7% vs a peer median of 7.1% (weaker than 76% of peers).Operating margin -12.7% vs peers 7.1% (weaker than 76% of peers).

How risky is Evolus?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 1.34 vs a peer median of 0.63 (weaker than 84% of peers).Beta 1.34 vs peers 0.63 (weaker than 84% of peers). A relative measure, not a bankruptcy probability.